FR15C0079I1 - - Google Patents
Info
- Publication number
- FR15C0079I1 FR15C0079I1 FR15C0079C FR15C0079I1 FR 15C0079 I1 FR15C0079 I1 FR 15C0079I1 FR 15C0079 C FR15C0079 C FR 15C0079C FR 15C0079 I1 FR15C0079 I1 FR 15C0079I1
- Authority
- FR
- France
- Prior art keywords
- hpv31
- polynucleotides
- synthetic
- protein
- vlps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45717203P | 2003-03-24 | 2003-03-24 | |
PCT/US2004/008677 WO2004084831A2 (en) | 2003-03-24 | 2004-03-19 | Optimized expression of hpv 31 l1 in yeast |
Publications (2)
Publication Number | Publication Date |
---|---|
FR15C0079I1 true FR15C0079I1 (en) | 2016-08-01 |
FR15C0079I2 FR15C0079I2 (en) | 2016-11-25 |
Family
ID=33098208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR15C0079C Active FR15C0079I2 (en) | 2003-03-24 | 2015-12-04 | OPTIMIZED EXPRESSION OF HPV 31 L1 IN YEAST |
Country Status (22)
Country | Link |
---|---|
US (2) | US7276243B2 (en) |
EP (1) | EP1608767B1 (en) |
JP (1) | JP4505452B2 (en) |
KR (1) | KR101080628B1 (en) |
CN (1) | CN100506999C (en) |
AT (1) | ATE546529T1 (en) |
AU (1) | AU2004224335B2 (en) |
BR (1) | BRPI0408639B8 (en) |
CA (1) | CA2519112C (en) |
EC (1) | ECSP056032A (en) |
ES (1) | ES2381964T3 (en) |
FR (1) | FR15C0079I2 (en) |
HK (1) | HK1090953A1 (en) |
IL (1) | IL171067A (en) |
IS (1) | IS2859B (en) |
MX (1) | MXPA05010285A (en) |
NL (1) | NL300772I1 (en) |
NO (2) | NO341527B1 (en) |
NZ (1) | NZ542246A (en) |
RU (1) | RU2356943C2 (en) |
WO (1) | WO2004084831A2 (en) |
ZA (1) | ZA200507178B (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
MY139500A (en) * | 2003-11-12 | 2009-10-30 | Merck Sharp & Dohme | Optimized expression of hpv 58 l1 in yeast |
KR101203403B1 (en) | 2004-03-24 | 2012-11-21 | 머크 샤프 앤드 돔 코포레이션 | Optimized expression of HPV 52 L1 in yeast |
JP4769247B2 (en) * | 2004-06-18 | 2011-09-07 | インディアン・イムノロジカルズ・リミテッド | Codon optimized HPV16L1 for Salmonella vaccine strain against human papillomavirus type 16 |
JP2006262846A (en) * | 2005-03-25 | 2006-10-05 | Niigata Bio Research Park Kk | Method for synthesizing and purifying 2-deoxy-scyllo-inosose with yeast and obtained 2-deoxy-scyllo-inosose |
US20100203496A1 (en) * | 2005-04-28 | 2010-08-12 | Taddeo Frank J | Fluorescent Multiplex HPV PCR Assays |
CN100392084C (en) * | 2006-03-13 | 2008-06-04 | 曾毅 | Recombinant adenovirus containing codon optimized type IIPV16L1 gene |
KR100904844B1 (en) * | 2006-08-28 | 2009-06-25 | 성균관대학교산학협력단 | A DNA Vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein |
US7709010B2 (en) * | 2007-03-09 | 2010-05-04 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
CN101113417B (en) * | 2007-06-22 | 2011-04-27 | 山东大学 | Establishment of HPV gene yeast external translating system |
CN101835797A (en) | 2007-11-23 | 2010-09-15 | 上海泽润生物科技有限公司 | Human papilloma virus major capsid protein L 1 gene and uses thereof |
US20110201086A1 (en) | 2010-02-12 | 2011-08-18 | Otsuka Pharmaceutical Co., Ltd. | Method for producing recombinant virus |
US9376727B2 (en) | 2010-05-25 | 2016-06-28 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically truncated probes |
ES2762230T3 (en) | 2011-06-24 | 2020-05-22 | Merck Sharp & Dohme | HPV vaccine formulations comprising an aluminum adjuvant and production methods thereof |
CN103215302B (en) * | 2012-01-21 | 2019-01-15 | 北京安百胜生物科技有限公司 | The method for generating HPV18 L1 albumen with expressed by Hansenula yeast system |
CN103361377B (en) * | 2012-03-28 | 2017-12-05 | 北京安百胜生物科技有限公司 | The method that HPV6 L1 albumen is produced with expressed by Hansenula yeast system |
CN108624614A (en) * | 2012-03-28 | 2018-10-09 | 北京安百胜生物科技有限公司 | The method for generating HPV11 L1 albumen with expressed by Hansenula yeast system |
CN104164374B (en) * | 2013-05-17 | 2019-10-22 | 北京安百胜生物科技有限公司 | The method for generating HPV31 L1 albumen with expressed by Hansenula yeast system |
CN104164373B (en) * | 2013-05-17 | 2019-04-02 | 北京安百胜生物科技有限公司 | The method for generating HPV68L1 albumen with expressed by Hansenula yeast system |
CN112280793B (en) * | 2013-09-29 | 2022-06-24 | 上海泽润生物科技有限公司 | Human papilloma virus gene, vector, strain and expression method |
CA2927434C (en) | 2013-10-16 | 2022-07-19 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
RU2546243C1 (en) * | 2014-02-13 | 2015-04-10 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Recombinant vaccine for prevention of human papillomavirus infection and method of its preparation |
US9951344B2 (en) * | 2014-10-10 | 2018-04-24 | Board Of Regents, The University Of Texas System | Exogenous terminators for controlling fungal gene expression |
EA201790944A1 (en) * | 2014-12-26 | 2017-11-30 | Айджин, Инк. | METHOD OF OBTAINING VIRUS-LIKE PARTICLES OF HUMAN PAPILLOMAVIRUS |
CN106148359A (en) * | 2015-03-30 | 2016-11-23 | 上海泽润生物科技有限公司 | Recombinant human papilloma virus 33 subtype protein is expressed |
CN106701797B (en) * | 2015-08-12 | 2021-06-15 | 北京康乐卫士生物技术股份有限公司 | 31 type recombinant human papilloma virus-like particle and preparation method thereof |
CN106831961B (en) | 2015-12-04 | 2019-11-05 | 厦门大学 | A kind of mutant of human papillomavirus type 58 L1 albumen |
WO2021013062A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 31 l1 protein |
IL295234A (en) | 2020-02-14 | 2022-10-01 | Merck Sharp & Dohme Llc | Hpv vaccine |
CN113073105B (en) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | Polynucleotide sequence for expressing HPV56L1, expression vector, host cell and application thereof |
AR126708A1 (en) | 2021-08-06 | 2023-11-08 | Merck Sharp & Dohme Llc | HPV VACCINE |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117591A0 (en) | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
PL335050A1 (en) | 1997-02-07 | 2000-03-27 | Merck & Co Inc | Synthetic genes gag hiv |
JP4434479B2 (en) | 1997-07-09 | 2010-03-17 | ザ・ユニバーシティ・オブ・クイーンズランド | Nucleic acid sequences and methods for selectively expressing proteins in target cells and tissues |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
FR2768748B1 (en) * | 1997-09-24 | 2001-06-08 | Rhone Poulenc Agrochimie | RECODING OF DNA SEQUENCES ALLOWING THEIR EXPRESSION IN YEAST AND PROCESSED YEAST OBTAINED |
US6991795B1 (en) * | 1998-08-14 | 2006-01-31 | Merck & Co., Inc. | Protein delivery system using human papillomavirus virus-like particles |
ES2275350T3 (en) * | 1998-08-14 | 2007-06-01 | MERCK & CO., INC. | PROTEIN ADMINISTRATION SYSTEM USING HUMAN PAPILOMAVIRUS VIRUS TYPE PARTICLES. |
WO2001014416A2 (en) * | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic papillomavirus genes optimized for expression in human cells |
US6436402B1 (en) * | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
PL365385A1 (en) | 2000-07-21 | 2005-01-10 | Glaxo Group Limited | Codon-optimized papilloma virus sequences |
WO2002008495A1 (en) | 2000-07-26 | 2002-01-31 | Shinko Pantec Co., Ltd. | Hydrogen/oxygen supply system |
AU2003217413A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Method for isolation and purification of expressed gene products in vitro |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
-
2004
- 2004-03-19 ES ES04757990T patent/ES2381964T3/en not_active Expired - Lifetime
- 2004-03-19 MX MXPA05010285A patent/MXPA05010285A/en active IP Right Grant
- 2004-03-19 JP JP2006507439A patent/JP4505452B2/en not_active Expired - Lifetime
- 2004-03-19 BR BRPI0408639A patent/BRPI0408639B8/en active IP Right Grant
- 2004-03-19 WO PCT/US2004/008677 patent/WO2004084831A2/en active Application Filing
- 2004-03-19 AU AU2004224335A patent/AU2004224335B2/en active Active
- 2004-03-19 AT AT04757990T patent/ATE546529T1/en active
- 2004-03-19 RU RU2005132603/13A patent/RU2356943C2/en active
- 2004-03-19 CN CNB2004800077258A patent/CN100506999C/en not_active Expired - Lifetime
- 2004-03-19 NZ NZ542246A patent/NZ542246A/en not_active IP Right Cessation
- 2004-03-19 CA CA2519112A patent/CA2519112C/en not_active Expired - Lifetime
- 2004-03-19 EP EP04757990A patent/EP1608767B1/en not_active Expired - Lifetime
- 2004-03-19 KR KR1020057017936A patent/KR101080628B1/en active IP Right Grant
- 2004-03-19 US US10/551,057 patent/US7276243B2/en not_active Expired - Lifetime
-
2005
- 2005-09-07 ZA ZA200507178A patent/ZA200507178B/en unknown
- 2005-09-12 IS IS8019A patent/IS2859B/en unknown
- 2005-09-20 EC EC2005006032A patent/ECSP056032A/en unknown
- 2005-09-22 IL IL171067A patent/IL171067A/en active IP Right Grant
- 2005-10-21 NO NO20054889A patent/NO341527B1/en active Protection Beyond IP Right Term
-
2006
- 2006-10-18 HK HK06111479.1A patent/HK1090953A1/en not_active IP Right Cessation
-
2007
- 2007-07-19 US US11/879,905 patent/US7482428B2/en not_active Expired - Lifetime
-
2015
- 2015-11-30 NL NL300772C patent/NL300772I1/nl unknown
- 2015-12-04 FR FR15C0079C patent/FR15C0079I2/en active Active
-
2018
- 2018-03-27 NO NO2018010C patent/NO2018010I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2018010I1 (en) | HPV 31 L1 protein | |
EP1687329B8 (en) | Optimized expression of hpv 58 l1 in yeast | |
TW200602490A (en) | Optimized expression of HPV 52 L1 in yeast | |
MY140664A (en) | Optimized expression of hpv 45 l1 in yeast | |
WO2001014416A3 (en) | Synthetic papillomavirus genes optimized for expression in human cells | |
AP1872A (en) | Virus-like particles of human papillomavirus. | |
TW200607858A (en) | Optimized expression of HPV 31 L1 in yeast | |
MXPA02003328A (en) | Vaccine. | |
MY138895A (en) | Optimized expression of hpv 31 l1 in yeast | |
TH108752B (en) | Optimized expression of HPV 52 L1 in yeast. | |
TH82139B (en) | Optimized Expression of HPV 45L1 in Yeast | |
AR045249A1 (en) | OPTIMIZED EXPRESSION OF HPV 31 L1 IN YEAST |